Find an expert

I am a basic science researcher with training in cell biology, genetics and research translation. My research investigates the female reproductive system by focusing on the contribution of individual cells. I aim to understand the influence of genetic architecture, differentiation and maturation on these individual cells and how this contributes to changes in the microenvironment that can contribute to disease initiation and progression.

After the completion of my PhD in 2008 at the University of Queensland, I undertook post-doctoral studies at the University of Bern, Department of Biomedical Research (DBMR), focusing on endometriosis, ovarian and endometrial cancer. I curated patient samples from clinical research trials to investigate inflammatory and metabolic components of reproductive tissue and disease and began developing patient-derived models of the endometrium. I established a relationship between endometriosis lesions, nerves and pain and how this interaction was mediated by inflammation. I further developed patient-derived in vitro models to understand the interaction between inflammation and hormonal response of endometriotic lesions and how this could be utilized to target current and novel treatments. On returning to Australia in 2016 I joined the Genomics of Reproductive Disorders laboratory to integrate genetic background into patient-derived in vitro models. I established the Endometriosis Research Queensland Study (ERQS) in collaboration with the Royal Brisbane and Women’s Hospital (RBWH) and extended in vitro models into complex multi-cellular assembloids (combinations of organoids and surrounding stromal cells).

Professor Mobli is a structural biologist and a group leader at the University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN). He is well known internationally for his contributions to the basic theory of multidimensional nuclear magnetic resonance and its applications to resolving the molecular structure of peptides and proteins, as well as studying their physiochemical properties and function. Mehdi's contributions to the field has been recognised by being appointed an Executive Editor of the AMPERE society's journal "Magnetic Resonance", and to the advisory board of the international Biological Magnetic Resonance Data Bank (BMRB) as well as serving on the board of directors of the Australia and New Zealand Society for Magnetic Resonance (ANZMAG). He is a former ARC Future Fellow and recipient of the ASBMB MERCK medal, the Australia Peptide Society's Tregear Award, the ANZMAG Sir Paul Callaghan medal and the Lorne Proteins Young Investigator Award (now Robin Anders Award).

Prof. Mobli's research group focuses on characterising the structure and function of receptors involved in neuronal signalling, with a particular focus on developing new approaches for the discovery and characterisation of modulators of these receptors through innovations in bioinformatics, biochemistry and and biophysics. This work has led to publication of more than 100 research articles attracting over 6,000 citations.

Associate Professor Muttenthaler is a medicinal chemist working at the interface of chemistry and biology with a strong passion for translational research. His research focuses on bioactive peptides and exploring Nature's biodiversity to develop advanced molecular tools, diagnostics, and therapeutics. His background in drug discovery and development, as well as his interdisciplinary training in the fields of chemistry, molecular biology and pharmacology, assist him in characterising these often highly potent and selective compounds to study their interactions with human physiology for medical innovations in pain, cancer, gut disorders and neurological diseases.

I am an Associate Professor in the School of Biomedical Sciences (SBMS) at The University of Queensland, where I teach physiology and lead research that explores how cells respond to stress, injury and disease. My work aims to better understand the molecular and cellular processes that influence health and disease, with a particular focus on areas relevant to cancer, heart disease, neurological conditions and emerging cell-based therapies.

I completed my doctorate at the University of Western Australia in Biochemistry and Cell Biology, where I studied how heart cells respond to signals that can drive abnormal tissue growth. I then undertook postdoctoral training in Singapore at the Institute of Molecular and Cell Biology, part of A*STAR, where my research expanded into understanding how the cytoskeleton, internal structures of cells, help control development and disease.

After returning to Australia, I was supported by national fellowships from the NHMRC and ARC, which enabled me to establish an internationally connected research program. My research brings together cell biology, imaging, computational approaches and emerging technologies to uncover how cells make critical decisions, including whether to survive or die under stress.

Alongside my research and teaching, I contribute to leadership within SBMS as Director of Research and support major research infrastructure initiatives across the Faculty of Health, Medicine and Behavioural Sciences (HMBS) as Academic Director of Research Infrastructure. I also serve on steering committees for UQ’s Viral Vector Core (VVC) and the Centre for Cardiovascular Health and Research (CCVHR), helping to strengthen the platforms and partnerships that support biomedical discovery and translation.

I completed my PhD in Neuroscience at UQ in 2009. After this, I undertook postdoctoral training in motor neuron disease/amyotrophic lateral sclerosis (MND/ALS) under the mentorship of neurologists at Royal Brisbane & Women's Hospital. In 2012, I received a MND Research Australia Bill Gole Fellowship to develop a research focus to study metabolic dysfunction in MND/ALS. I started my independent research group at UQ in 2015, after receiving the Scott Sullivan MND Research Fellowship to lead a translational program to define the contribution of altered metabolic homeostasis to MND/ALS pathophysiology. In 2017, I relocated my laboratory to the Australian Institute for Bioengineering and Nanotechnology to introduce the use of human stem cells for disease modelling into my reserach program. In 2020, I was awarded a FightMND Mid-Career Research Fellowship to transition into clinical trials.

My current research integrates studies in MND/ALS patients with studies in human-derived cell models (stem cell-derived neurons, human primary myosatellite cells, human myotubes) and mouse models of MND/ALS. I have served as lead investigator or co-investigator on several projects aimed at defining the mechanisms that drive MND/ALS and identifying therapeutic strategies for the disease. Projects have led to the expediting of clinical trials (NCT03506425; NCT04788745, NCT05959850). In 2021, I established the MND at UQ Collective to enhance national and international collaboration, and to facilitate community consultation to drive scientific and clinical discoveries in ALS and FTD (www.uq.edu.au/mnd-collective).

I have received invitations to contribute to high impact review articles (i.e., Brain, Nat Rev Neurol), and have received >20 invitations to speak at conferences including: 33rd International ALS/MND Symposium (2022, Plenary), 64th Japanese Society of Neurology Meeting (2023, Tokyo; Plenary), 3rd International Pan-Asian Consortium for Treatment and Research in ALS (PACTALS) Congress (2023, Kuala Lumpur), 18th International Congress on Neuromuscular Diseases (2024, Perth).

Dr Quan Nguyen is a Group Leader at the Institute for Molecular Bioscience (IMB), The University of Queensland, where he leads the Genomics and Machine Learning (GML) Laboratory. His research focuses on understanding pathological processes within tissues to identify biomarkers for early diagnosis, patient stratification, and prediction of treatment response. His work integrates statistical machine learning techniques with advanced genomic technologies, combining single-cell and spatiotemporal sequencing data with tissue imaging to uncover causal links between genotypes and phenotypes across biological scales, from single cell, to tissue microenvironment, organ, multi-organ and population level. By studying cell-cell interactions, his research also contributes to the discovery of novel drug targets and improved understanding of drug mechanisms and toxicity. The GML Laboratory also develops spatiotemporal experimental platforms for large-scale biomarker profiling and validation in preclinical models and patient cohorts.

Dr Nguyen completed a PhD in Bioengineering at the University of Queensland in 2013, postdoctoral training in Bioinformatics at RIKEN institute in Japan in 2015, a CSIRO Office of Chief Executive (OCE) Research Fellowship in 2016, an IMB Fellow in 2018, an Australian Research Council DECRA fellowship, 2019-2021), and is a National Health and Medical Research Council Leadership Fellow (EL2 2022-2026 and L1 2027-2031). He has authored 86 publications in top-tier journals, like Cell, Nature Genetics, and Nature Method, averaging ~45.5 citations per paper, and led the development of 14 software tools with over 250,000 downloads. His recognised expertise is demonstrated through 14 national/international awards, numerous invited talks (21 international, 42 national), invited grant reviews for funding bodies in nine countries, and active editorial roles for BMC Cancer and Genome Medicine. His commitment to propelling the field forward is evident in leading roles within key consortia and forums and his dedication to organise training workshops and conferences. He has secured over $31 million in grant funding as a chief investigator from national and international funding agencies (e.g., ARC, NHMRC, MRFF, DoD, NCI) and from industry partners, with approximately $11million directly supporting his lab's groundbreaking work.

Megan O’Mara is a Professor and Group Leader at the Australian Institute for Bioengineering and Nanotechnology (AIBN), UQ. Her group uses multiscale modelling techniques to understand how changes in the biochemical environment of the cell membranes alters membrane properties and modulates the function of membrane proteins. She has research interests in multidrug resistance, computational drug design and delivery, biopolymers, and personalized medicine. Megan completed her PhD in biophysics at the Australian National University in 2005 before moving to the University of Calgary, Canada, to take up a Canadian Institutes of Health Research Postdoctoral Fellowship. In 2009, she returned to Australia to join University of Queensland’s School of Chemistry and Molecular Biosciences as a UQ Postdoctoral Fellow, before commencing an ARC DECRA in 2012 where she continued her computational work on membrane protein dynamics. In 2015, Megan joined the Research School of Chemistry, Australian National University in 2015 as Rita Cornforth Fellow and Senior Lecturer. In 2019 she was promoted to Associate Professor and was Associate Director (Education) of the Research School of Chemistry ANU in 2019-2021. In April 2022 she relocated to AIBN.

I studied Technical Mathematics at the Vienna University of Technology. I also earned a Master's degree in Law and I finished the first ("non-clinical") part of Medical Studies at the University of Vienna. I earned my PhD in Applied Mathematics at the University of Vienna in 2007. My PhD advisor was Christian Schmeiser, my co-advisor was Peter Markowich. I spent several months at the University of Buenos Aires working with C. Lederman and at the ENS-Paris rue d'Ulm in the group of B. Perthame.

Before coming to UQ, I held post-doc positions at the Wolfgang Pauli Insitute (Vienna), University of Vienna and the Austrian Academy of Sciences (RICAM). In 2013 I won an Erwin Schrödinger Fellowship of the Austrian Science Fund (FWF). I was a post-doc researcher in the group of Alex Mogilner first at UC Davis, then at the Courant Institute of Math. Sciences (New York University).

I moved to UQ in Dec. 2016. More recently, in 2024, I spent 4 months at the department of Mathemetics of the U. of Heidelberg as a visiting scientist.

Biography

Dr Huadong Peng is a Group Leader and Senior Research Fellow at the UQ's Biosustainability Hub, Australian Institute for Bioengineering and Nanotechnology (AIBN), UQ. He is a Future Academic Leader in the Australia’s Food and Beverage Accelerator (FaBA), and part of ARC Centre of Excellence in Synthetic Biology (CoESB). He earned his PhD from Monash University in Nov 2018, followed by postdoctoral training at Imperial College London and the Technical University of Denmark until Dec 2023. Prior to his PhD, he received his Master Degree from the University of Chinese Academy of Sciences in 2013 and a Bachelor Degree from China Three Gorges University in 2010. Additionally, he worked as a research associate at Novozymes (now Novonesis) from Nov 2013 to Jan 2015.

Since Jan 2024, Dr Peng has led the Yeast Engineering and Synthetic Biology (YESBio) research group (10-15 members), focusing on sustainable biomanufacturing. His research interests include 1) developing innovative synthetic biology tools, such as gene assembly methods, CRISPR-based genome editing tools, and biosensors; 2) modular metabolic engineering for advanced microbial cell factories, 3) synthetic microbial communities and 4) emerging Bio+ enabling technologies for applications in food ingredients, biochemicals, biofuels, and biomedicines.

Dr Peng secured $4.8M funding as Chief Investigator ($2.1M to his team), including the prestigious Marie Skłodowska-Curie Fellowship. He has published 40+ peer-reviewed papers in prestigious journals, including Nature Microbiology, Nature Chemical Biology, Nature Communications. He actively contributes to the scientific community through editorial roles, including Associate Editor for Frontiers in Bioengineering and Biotechnology and Youth Editor for The Innovation (IF 26), BioDesign Research and mLife. He is also an invited peer reviewer for 30+ international journals and grants such as Nature Synthesis, ACS Synthetic Biology, etc.

Dr Peng is looking for highly motivated Honours, Master and PhD students, and highly competitive full scholarship may be provided. The University of Queensland ranks in the top 50 as measured by the Performance Ranking of Scientific Papers for World Universities. The University also ranks 45 in the QS World University Rankings, 52 in the US News Best Global Universities Rankings, 60 in the Times Higher Education World University Rankings and 55 in the Academic Ranking of World Universities.

Industry

Dr Peng is keen to translate the technologies developed by his team into real-world commercial applications, including advanced microbial cell factories, synthetic microbial communities, and optimised bioprocesses. These innovations enable the delivery of sustainable bio-solutions for industrial sectors spanning agri-food, industrial biotechnology and human health. He has established close collaborations with industry partners such as Woodside Energy, Noumi Operations, and Cauldron Fermentation, and he is actively engaging with additional partners, including Levur and NeweraBio.

Dr Peng has experience consulting with multiple companies and is open to taking on casual consulting roles as opportunities arise.

Selected Funding & Awards

Dr Peng has secured $4.8M funding as Chief Investigator ($2.1M to his team), including

• 2025 Australia’s Food and Beverage Accelerator (FaBA)-Cauldron ferm, $2M, CIB
• 2025 Australia’s Food and Beverage Accelerator (FaBA)-Noumi Operations, $2M, co-CIA
• 2025 NCRIS Synthetic Biology Voucher Scheme, $40K, CIA
• 2024 UQ Biosustainability hub seed funding, $50K, CIA
• 2024 Australia’s Food and Beverage Accelerator seed funding, $160K, CIA
• 2023 Chinese Government Award for Outstanding Self-financed Students Abroad, $15K
• 2022 Marie Skłodowska-Curie Fellowship ($266K, 8% success rate)

Key Publications (#, co-first author; *, corresponding author)

1. Chen, H.#, Peng, H.#, Ellis, T., & Ledesma-Amaro, R. Programmable cell–cell adhesion in synthetic yeast communities for improved bioproduction. Nature Chemical Biology 2026. https://doi.org/10.1038/s41589-025-02081-1
2. Peng, H.; Darlington, A. P. S.; South, E. J.; Chen, H.-H.; Jiang, W.; Ledesma-Amaro, R*. A molecular toolkit of cross-feeding strains for engineering synthetic yeast communities. Nature Microbiology 2024. 9(3), 848-863.
3. Park Y.-K., Peng H, Hapeta P., Sellés Vidal L. and Ledesma-Amaro R*. Engineered cross-feeding creates inter- and intra-species synthetic yeast communities with enhanced bioproduction. Nature Communications 2024, 15(1): 8924.
4. Aulakh S#, Vidal L#, South E#, Peng H, Varma S, Herrera-Dominguez L, Ralser M*, Ledesma-Amaro R*. Spontaneously establishing syntrophic yeast communities improves biosynthetic yield through shared labour. Nature Chemical Biology 2023, 19(8), 951-961.
5. Jiang W, Hernández V-D, Peng H, Liu L, Haritos VS, Ledesma-Amaro R* Metabolic engineering strategies to enable microbial utilization of C1 feedstocks. Nature Chemical Biology 2021, 17(8), 845-855. `
6. P Gao, Sun H., Ledesma-Amaro R., Marcellin E. and Peng H.* Advancements and Challenges in the Bioproduction of Raspberry Ketone by Precision Fermentation. Future Foods 2025: 100606.
7. Wen, Q., Xu, X., He, Q., Wang, C., Chen, Z., Zhong, W., Peng, H.*, Yang, M.*, & Xing, J*. Dual-pathway engineering enables robust vanillin bioproduction in Pseudomonas putida. Chemical Engineering Journal 2025, 526.
8. Peng, H.*; Chen, R.; Shaw, W. M.; Hapeta, P.; Jiang, W.; Bell, D. J.; Ellis, T.; Ledesma-Amaro, R*. Modular Metabolic Engineering and Synthetic Coculture Strategies for the Production of Aromatic Compounds in Yeast. ACS Synthetic Biology 2023, 12 (6), 1739-1749.
9. Peng, H.; He, L.; Haritos, V. S*. Flow-cytometry-based physiological characterisation and transcriptome analyses reveal a mechanism for reduced cell viability in yeast engineered for increased lipid content. Biotechnology for Biofuels 2019, 12 (1), 98.
10. Peng, H.; Chen, H.; Qu, Y.; Li, H.; Xu, J*. Bioconversion of different sizes of microcrystalline cellulose pretreated by microwave irradiation with/without NaOH. Applied Energy 2014, 117 (0), 142-148

Updated on 2 Jan 2026

Dr Giovanni Pietrogrande is based at the Australian Institute for Bioengineering and Nanotechnology (AIBN), where he is the Synthetic Neuroimmunology Theme Leader.

He leads the development of advanced human brain and spinal cord organoid models to study neuroinflammation, demyelination and neurodegeneration, with a particular focus on how microglia, oligodendrocytes and other neural cells interact to drive diseases such as multiple sclerosis and motor neuron disease, and on using this knowledge to identify and test new therapeutic strategies. His research program is supported by competitive funding from HNMRC, MS Australia, MND Research Australia and FightMND, underscoring the translational impact and clinical relevance of his work.

Together with his team, he works on a broad range of problems, from engineering next-generation immune-based cell therapies and endowing central nervous system organoids with a functional immune system, to modelling their interactions with immune cells to fully reproduce neurodegenerative and neuroinflammatory pathologies. The group also leverages synthetic biology to design new strategies to rebalance neuroinflammation, promote remyelination and repair neural circuits.

I received my Bachelor's in Biology (2001) from Yarmouk University in Jordan, followed by postgraduate degrees from the University of Houston in Houston-Texas (2002-2007). My studies are integrative in nature, joining the best of both the Neuroscience world and Circadian Biology (the study of biological clocks). In the laboratory of Prof. Arnold Eskin, I investigated how processes as complex as learning and memory are modulated by biological clocks i.e. the circadian (about 24 hours) system, using Aplysia californica as the experimental model. After completing my Master's in Science in 2005, my research focused on the mechanism by which biological clocks modulate learning and memory. This work was performed in the laboratories of Prof. Gregg Cahill and Prof. Greg Roman, experts in chronobiology and behavioral neuroscience, respectively. Using Zebrafish as a model system, I investigated the role of melatonin, a night-time restricted hormonal signal, in modulating long-term memory consolidation. My findings, published in Science in 2007, shows that the circadian system via the cyclic night-time confined synthesis/release of melatonin “the hormone of darkness” functions as a modulator, shaping daily variations in the efficiency by which memories are processed. After receiving my Ph.D. in 2007, I joined as a postdoctoral fellow the laboratory of the pharmacologist and melatonin researcher Prof. Margarita Dubocovich. My postdoctoral work engaged in elucidating the role of melatonin in circadian physiology and pharmacology during development and ageing in rodents (Mus musculus) and non-human primates (Macaca mulatta) at the Feinberg School of Medicine (Northwestern University-Chicago) and the State University of New York (SUNY). From 2010-2015, I held a teaching/research position in the Dr. Senckenbergische Anatomy and the Dept. of Neurology at the Goethe University in Frankfurt-Germany. During this time, I was involved in teaching gross human anatomy while continuing my endeavor in understanding the mechanistics involved in shaping memory processes (acquisition, consolidation and retrieval) by the circadian system.

I am a neuroscientist investigating how cellular signalling and neuron–glia interactions shape brain development, neural circuit function and myelination across the lifespan, and how disruption of these processes contributes to neurodevelopmental and neurodegenerative disorders. My research focuses on neural progenitor cells, oligodendrocyte biology, myelination and neural circuit function, with the broader goal of understanding disease mechanisms and identifying therapeutic targets that can improve the treatment of neurological disorders.

I completed my PhD at the University of Tasmania, investigating ion channel signalling in oligodendrocyte progenitor cells and its role in cell survival, neural circuit function and myelination. I subsequently undertook postdoctoral research at The University of Queensland, including at the Queensland Brain Institute, where I investigated neural progenitor function, neuronal migration and cortical development in models of neurodevelopmental disorders. At Mater Research–UQ, my research has focused on oligodendrocyte dysfunction, myelination and cellular signalling in neurological disease, including multiple sclerosis-like pathology.

Across these research programs, I have developed expertise in developmental and cellular neuroscience, neural progenitor biology, neuron–glia interactions, oligodendrocyte biology, myelination and neural circuit function, using molecular and cellular approaches, advanced microscopy, electrophysiology, animal models and behavioural neuroscience. My broader research direction is to understand how dysfunction across different neural cell populations contributes to disease progression and how this knowledge can be translated into new approaches to prevent, treat or modify neurological disease.

Alongside my research, I contribute to tertiary teaching, student supervision and scientific communication across neuroscience, psychology and biomedical sciences. I am particularly interested in research-informed education and in developing the next generation of scientists by sharing scientific knowledge, technical expertise and practical research skills.

Dr Melanie Robitaille is a Senior Research Fellow working with the Calcium Signalling in Therapeutics Team (CaSTT) in the School of Pharmacy and Pharmaceutical Sciences. This team specializes in the development and application of novel methodologies and cellular assays in drug discovery, including the use of genetically encoded indicator for high-content imaging in live cells.

Her interests are to elucidate how calcium signals are remodelled in disease states, to identify calcium transporters as new therapeutic targets and to develop molecular and cellular screening tools to be used in drug development programs. She has an established profile in cellular and molecular biology, with high expertise in plasmid cloning, lentiviral transduction and the use of CRISPR/Cas9 to modulate gene expression.

Professor Eugeni Roura is a nutritionist with interests in digestive physiology and gut health, chemosensory science (including taste and smell) and transgenerational mechanisms relevant to chickens, pigs and humans. Eugeni holds a Veterinary and PhD degrees from the Autonomous University of Barcelona and a MPhil and post-doctoral appointments at the University of California (Davis). He developed a sixteen-year career in the feed and food industries before joining The University of Queensland (2010) where he currently leads the Nutrition & Chemosensory Science Group. The main current research areas in animal science include appetite modulation in chickens and pigs, nutrition interventions to boost embryonic/foetal development (including “in ovo”), and strategies to improve sustainability of chicken meat, egg and pork production. In human nutrition the focus is around food allergies and appendicitis. In 2011, Eugeni joined the UQ School of Biomedical Sciences as an Affiliated Lecturer. Since 2010 he has graduated 20 PhD students in Australia, published more than 100 peer-reviewed publications, and has been invited as keynote speaker to more than 50 national and international scientific meetings. He is currently serving as President of the World’s Poultry Science Association (Australia branch), Director of the AgriFutures Chicken Meat Consortium, and member of the National Committee for Nutrition (Australian Academy of Sciences), R&D and Education Committees of the Australasian Pork Research Institute Ltd., and the Federation of Oceania Nutrition Societies. He was the recipient of the Nutrition Society of Australia 2024 Medal award.

I am a molecular biologist/biochemist and HFSP postdoctoral researcher at the School of School of Chemistry and Molecular Biosciences. My research bridges the fields of functional proteomics and evolutionary biology, with a particular focus on how proteins and their post-translational modifications have evolved to shape and enable the evolution of key animal traits. Using mass spectrometry as my main analytical tool, I study early-branching animals such as sponges, ctenophores, and cnidarians to uncover the post-translational innovations underlying the emergence of multicellularity, the nervous and immune systems, and symbiotic interactions.

My current focus is on the evolution of protein N-glycosylation, a modification central to protein stability, folding, cell-cell and cell-ECM adhesion, recognition and communication, and therefore pivotal to the evolution of animals.

I completed my PhD (2019-2023) at the European Molecular Biology Laboratory (EMBL) Heidelberg, Germany in the group of Prof. Detlev Arendt, as a Marie Skłodowska-Curie Fellow within the ITN IGNITE network, where I combined functional proteomics with 3D imaging to uncover the molecular basis of coordinated contractions in nerveless sponges. This work revealed an ancient relaxant-inflammatory response underlying sponge deflation (Current Biology, 2024) and, in parallel, developed a protein structure-based framework for cross-phyla protein annotation in poorly annotated non-model species (Genome Biology, 2023).

I routinely work with mass spectrometry-based -omics (proteomics, glycoproteomics, glycomics) in non-model organisms in the Schulz lab. I welcome collaborations involving PTM discovery, glycoproteomics, and protein annotation in non-model species, as well as anyone simply interested in evolution and proteins.

I am Professor, NHMRC Investigator Fellow (EL2) and group leader (Exosome Biology Laboratory) at UQ Centre for Clinical Research. I am nationally and internationally (>20 invitations to international meetings in the last 5 years) acknowledged key opinion leader on Extracellular Vesicle (rated 3th worldwide (Top 0.015%) and 1st in Australia in expertise for “Extracellular Vesicles and Exosomes” on Expertscape) and biomarker discovery (140 publications, and >8000 citations in the last 7 year). I have made a major conceptual contribution to EV biology with diagnostic and therapeutic implications. In the last 8 years, my primary research and commercialisation activities have focused on the identification and validation of biomarkers, and development of In Vitro Multivariate Index Assays for clinically relevant complications (including ovarian cancers, and obstetrical syndromes) and their translation into clinical applications. In Academia, I have pursued these objectives through the development and leadership of clinical translation research teams and facilities, both in Australia and overseas. For example, I had a leadership role in established the Centre for Clinical Diagnostics (CCD). Within the UQCCR, I established an exosome research team to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Much of our effort in this field of endeavour has involved optimising isolation methods for extracellular vesicles and their analytical analysis - including the use of protein solution array (e.g. Luminex), mass spectrometry profiling (using MS/MS SWATH) and more recently miRNA analysis.

Dr Anuj Sehgal completed his at the Roslin Institute, University of Edinburgh (UK) (2013-2017), where he developed a long-term research passion for investigating the development and function of the immune system. In 2018, Dr Sehgal joined the Mater Research Institute as a Research Officer. Some key highlights of Anuj's work has identified unique associations between macrophages and stem cell niches across the body, including intestinal stem cells (Sehgal et al., 2018, Nat. Comms) and HSC-niches in the bone marrow and peripheral lymphoid organs (Kaur*, Sehgal* et al. 2021 J. Hem. Onco). In 2022, Anuj diverted from academic research to contract clinical trials at the Wesley Research Institute. More recently, Anuj has rejoined UQ as a Flow Cytometry research fellow in the Chappell Lab under the ViceBio team, working on cell mediated immune responses in RSV preclinical and clinical trials.

Dr Abbas Shafiee is leading a multidisciplinary program in Regenerative Dermatology and Biofabrication. His research integrates stem cell biology, organoid technology, and bioengineering to develop advanced human models and regenerative therapies for skin repair and disease.

Dr Shafiee completed his PhD in stem cell biology, discovering a previously unknown vascular stem cell population, termed the Meso-Endothelial Bipotent Progenitor, and mapping its molecular signatures (Stem Cell Reports 2018). This seminal discovery advanced the understanding of human vascular development and regeneration.

He subsequently joined Distinguished Professor Dietmar Hutmacher’s group, where he developed humanised tissue-engineered bone and tumour models that mimic cancer metastasis and tumor–stroma interactions. These models (International Journal of Cancer (2018), Biomaterials (2018, 2020), and Bone Research (2019), Acta Biomaterialia (2020), Bone (2022)) provided unprecedented insights into human-specific cancer biology and preclinical drug testing.

Dr Shafiee joined Metro North Health (MNH) in 2020 to lead a research program and develop, implement, and evaluate the applications of 3D printing, scanning, cell therapies, and biofabrication technologies in skin wound settings, and dermatology research. His team has developed vascularised and immune-integrated skin organoids and 3D-printed bioengineered grafts that accelerate wound closure with minimal scarring (Biomaterials 2021; Advanced Healthcare Materials (2022; 2025); Small 2024; Burns & Trauma 2025). These breakthroughs underpin new patient-specific skin disease models, and drug screening platforms (Acta Biomaterialia 2025). He is the lead inventor on an international patent protecting an Optimized Method for Generating Human Skin Organoids (WO/2025/097221), which forms the foundation for emerging commercial and translational partnerships. This body of work led to the establishment of the International Consortium for Organoid Research in Dermatology, a global network accelerating discovery and translation in skin biology, rare genetic skin diseases, and regenerative dermatology.

Dr Shafiee has secured >AUD $2.4M as Chief Investigator (>AUD $1.1M as CIA) in competitive research funding from national, international, philanthropic, and industry-supported schemes. Dr Shafiee has supervised more than ten PhD, Masters, honours students and contributed to multiple professional, editorial, and scientific leadership roles. He has authored over 88 peer-reviewed publications (>5,500 citations, h-index 40) and delivered more than 50 invited, keynote, and plenary presentations internationally. He serves on multiple professional and editorial boards, including Australian Wound & Tissue Repair Society (AWTRS), Burns & Trauma, and Engineered Regeneration. In recognition of his pioneering contributions to regenerative medicine and science communication, he has received multiple honours, including the 2024 Frazer Institute Rising Star Award, the 2025 AWTRS EMCR Award, and the 2025 Queensland Young Tall Poppy Science Award, and selection as a 2026 TEDx speaker, recognising his leadership in translating complex science to global audiences.

He actively engages with the media, schools, and community programs to inspire future scientists and raise public awareness of regenerative medicine and organoid technologies. His outreach has reached millions nationwide through major media coverage (e.g., The Australian, 7NEWS, ABC NEWS) .

Research areas:

• Human iPSC-derived skin organoids and skin-on-chip models
• Vascularization and immune integration in skin tissue engineering
• Rare genetic skin diseases and personalized regenerative therapies
• Translational biofabrication and wound healing technologies
• Organoid-based preclinical drug discovery platforms

Honours, Masters, and PhD opportunities are available for motivated students interested in regenerative dermatology, biofabrication, and organoid biology.